Editas Medicine Quarterly Balance Sheets Chart
Quarterly
|
Annual
Editas Medicine Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 138,542,000 | 138,692,000 | 131,541,000 | 95,832,000 | 64,441,000 | 69,227,000 | 123,652,000 | 82,537,000 | 220,817,000 | 129,021,000 | 141,522,000 | 210,704,000 | 169,401,000 | 210,881,000 | 203,519,000 | 259,884,000 | 337,834,000 | 354,918,000 | 139,682,000 | 279,576,000 | 485,819,000 | 232,850,000 | 238,183,000 | 104,772,000 | 210,605,000 | 157,932,000 | 134,776,000 | 111,701,000 | 131,924,000 | 217,671,000 | 146,630,000 | 86,542,000 | 144,096,000 | 351,552,000 | 185,323,000 | 199,874,000 | 217,650,000 | 229,204,000 | 143,180,000 |
| marketable securities | 39,959,000 | 82,272,000 | 138,372,000 | 169,256,000 | 214,671,000 | 226,944,000 | 199,459,000 | 267,080,000 | 211,151,000 | 189,418,000 | 202,752,000 | 208,913,000 | 283,157,000 | 277,481,000 | 296,326,000 | 297,957,000 | 272,719,000 | 270,415,000 | 262,428,000 | 215,729,000 | 112,901,000 | 182,143,000 | 218,957,000 | 227,844,000 | 107,325,000 | 184,133,000 | 234,179,000 | 225,791,000 | 212,156,000 | 141,150,000 | 182,509,000 | 209,149,000 | 180,699,000 | ||||||
| accounts receivable | 588,000 | 510,000 | 16,266,000 | 126,000 | 244,000 | 245,000 | 10,187,000 | 2,422,000 | 2,286,000 | 242,000 | 5,145,000 | 120,000 | 713,000 | 1,371,000 | 267,000 | 251,000 | 331,000 | 672,000 | 6,048,000 | 1,055,000 | 1,865,000 | 1,832,000 | 418,000 | 311,000 | 12,000 | 30,000 | 43,000 | 362,000 | 931,000 | 679,000 | 695,000 | 820,000 | 945,000 | 88,000 | 1,122,000 | 1,195,000 | 1,108,000 | 1,019,000 | |
| prepaid expenses and other current assets | 3,707,000 | 3,369,000 | 3,136,000 | 5,925,000 | 6,998,000 | 9,139,000 | 7,531,000 | 6,564,000 | 6,724,000 | 5,777,000 | 7,335,000 | 6,892,000 | 8,106,000 | 7,298,000 | 7,198,000 | 9,516,000 | 5,408,000 | 6,311,000 | 10,929,000 | 10,467,000 | 9,541,000 | 8,281,000 | 6,286,000 | 6,284,000 | 6,298,000 | 5,002,000 | 5,791,000 | 5,018,000 | 3,795,000 | 3,060,000 | 2,381,000 | 2,030,000 | 2,257,000 | 1,289,000 | 1,772,000 | 2,453,000 | 2,373,000 | 1,874,000 | 786,000 |
| total current assets | 182,796,000 | 224,843,000 | 289,315,000 | 271,139,000 | 286,354,000 | 305,555,000 | 340,829,000 | 358,603,000 | 440,978,000 | 324,458,000 | 356,754,000 | 426,629,000 | 461,377,000 | 497,031,000 | 507,310,000 | 567,608,000 | 616,292,000 | 632,316,000 | 419,087,000 | 506,827,000 | 610,126,000 | 425,106,000 | 463,844,000 | 339,211,000 | 324,240,000 | 347,067,000 | 374,776,000 | 342,553,000 | 348,237,000 | 362,812,000 | 332,199,000 | 298,416,000 | 327,872,000 | 353,786,000 | 187,183,000 | 203,449,000 | 221,218,000 | 232,186,000 | 144,985,000 |
| property and equipment | 4,576,000 | 8,182,000 | 14,497,000 | 15,419,000 | 14,156,000 | 13,257,000 | 12,032,000 | 11,559,000 | 12,846,000 | 13,211,000 | 15,569,000 | 15,494,000 | 16,198,000 | 17,258,000 | 17,118,000 | 15,631,000 | 14,910,000 | 14,095,000 | 14,020,000 | 14,069,000 | 12,895,000 | 12,218,000 | 10,887,000 | 10,075,000 | 8,530,000 | 7,991,000 | 40,232,000 | 39,699,000 | 39,915,000 | 39,551,000 | 39,442,000 | 39,092,000 | 39,358,000 | 39,636,000 | 40,378,000 | 37,072,000 | 26,741,000 | 15,003,000 | 2,130,000 |
| right-of-use assets | 19,011,000 | 26,429,000 | 32,554,000 | 35,728,000 | 36,951,000 | 31,443,000 | 33,680,000 | 31,936,000 | 34,811,000 | 36,344,000 | 43,648,000 | 22,532,000 | 20,666,000 | 23,457,000 | 26,173,000 | 27,801,000 | 30,314,000 | 29,305,000 | 25,128,000 | 26,398,000 | 28,569,000 | 27,022,000 | 28,761,000 | ||||||||||||||||
| restricted cash and other non-current assets | 4,198,000 | 4,198,000 | 5,223,000 | 5,281,000 | 8,145,000 | 9,487,000 | 8,588,000 | 5,755,000 | 5,253,000 | 6,753,000 | 5,253,000 | 7,530,000 | 7,530,000 | 7,316,000 | 6,811,000 | 6,781,000 | 6,780,000 | 6,688,000 | 4,703,000 | 3,877,000 | 3,891,000 | 2,391,000 | 5,393,000 | 5,392,000 | 5,378,000 | 5,378,000 | 5,378,000 | 5,378,000 | 5,378,000 | 1,619,000 | 1,619,000 | 1,619,000 | 1,619,000 | 1,619,000 | 1,621,000 | 1,632,000 | 1,643,000 | 1,619,000 | |
| total assets | 210,581,000 | 263,652,000 | 341,589,000 | 327,567,000 | 384,801,000 | 440,347,000 | 499,153,000 | 504,650,000 | 541,953,000 | 464,105,000 | 514,321,000 | 531,029,000 | 580,833,000 | 623,108,000 | 677,483,000 | 717,019,000 | 755,880,000 | 780,294,000 | 572,602,000 | 597,157,000 | 655,481,000 | 466,737,000 | 508,885,000 | 372,359,000 | 355,625,000 | 378,916,000 | 420,386,000 | 387,630,000 | 393,530,000 | 403,982,000 | 373,260,000 | 339,127,000 | 368,849,000 | 395,041,000 | 229,182,000 | 242,153,000 | 249,602,000 | 248,808,000 | 149,363,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||||||||||||||||||
| accounts payable | 6,723,000 | 5,465,000 | 5,493,000 | 12,491,000 | 13,769,000 | 7,966,000 | 8,269,000 | 10,411,000 | 8,066,000 | 9,047,000 | 9,511,000 | 6,836,000 | 6,169,000 | 4,693,000 | 5,050,000 | 3,402,000 | 4,415,000 | 8,910,000 | 6,408,000 | 5,158,000 | 6,339,000 | 10,394,000 | 5,843,000 | 6,624,000 | 3,981,000 | 6,557,000 | 5,327,000 | 5,040,000 | 4,661,000 | 8,996,000 | 4,020,000 | 6,976,000 | 8,156,000 | 15,233,000 | 4,640,000 | 3,718,000 | 5,844,000 | 2,909,000 | 1,381,000 |
| accrued expenses | 48,068,000 | 47,488,000 | 45,859,000 | 28,785,000 | 27,669,000 | 31,481,000 | 34,563,000 | 30,278,000 | 27,896,000 | 31,560,000 | 31,296,000 | 19,259,000 | 20,105,000 | 15,787,000 | 20,192,000 | 14,575,000 | 18,627,000 | 15,132,000 | 24,046,000 | 20,307,000 | 10,194,000 | 8,669,000 | 22,120,000 | 8,138,000 | 8,169,000 | 5,642,000 | 12,813,000 | 11,341,000 | 11,029,000 | 7,767,000 | 11,049,000 | 8,450,000 | 11,160,000 | 6,769,000 | 17,439,000 | 9,492,000 | 7,846,000 | 7,251,000 | 5,456,000 |
| liability for sale of future revenues, current | 5,000,000 | 5,000,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||
| deferred revenue, current | 2,000,000 | 6,221,000 | 14,684,000 | 14,684,000 | 14,684,000 | 8,221,000 | 8,221,000 | 8,221,000 | 8,221,000 | 8,221,000 | 4,221,000 | 5,817,000 | 11,333,000 | 22,667,000 | 34,000,000 | 32,704,000 | 20,943,000 | 19,874,000 | 40,940,000 | 40,642,000 | 23,514,000 | 46,019,000 | 56,036,000 | 23,400,000 | 15,712,000 | 8,725,000 | 7,386,000 | 13,323,000 | 13,238,000 | 13,239,000 | 13,239,000 | ||||||||
| operating lease liabilities | 6,146,000 | 13,161,000 | 14,652,000 | 16,393,000 | 18,184,000 | 12,356,000 | 12,164,000 | 9,693,000 | 10,330,000 | 8,327,000 | 11,082,000 | 11,973,000 | 10,147,000 | 10,206,000 | 10,309,000 | 10,263,000 | 8,974,000 | 7,264,000 | 6,811,000 | 6,342,000 | 6,650,000 | 5,649,000 | 5,804,000 | ||||||||||||||||
| total current liabilities | 65,937,000 | 73,114,000 | 77,225,000 | 72,353,000 | 74,306,000 | 66,487,000 | 63,217,000 | 58,603,000 | 54,513,000 | 57,155,000 | 60,110,000 | 42,289,000 | 36,421,000 | 36,503,000 | 46,884,000 | 50,907,000 | 66,016,000 | 64,010,000 | 58,208,000 | 54,816,000 | 68,150,000 | 68,869,000 | 59,963,000 | 66,787,000 | 72,867,000 | 41,029,000 | 35,900,000 | 26,086,000 | 24,020,000 | 30,994,000 | 36,707,000 | 29,496,000 | 48,686,000 | 50,287,000 | 33,083,000 | 13,757,000 | 13,721,000 | 10,222,000 | 6,925,000 |
| operating lease liabilities, net of current portion | 14,989,000 | 17,972,000 | 20,380,000 | 22,095,000 | 20,514,000 | 21,783,000 | 24,372,000 | 24,918,000 | 26,856,000 | 28,810,000 | 32,864,000 | 9,328,000 | 10,110,000 | 12,957,000 | 16,069,000 | 18,430,000 | 21,282,000 | 21,621,000 | 19,324,000 | 20,368,000 | 22,153,000 | 21,530,000 | 23,277,000 | ||||||||||||||||
| liability for sale of future revenues - non-current | 51,670,000 | 49,579,000 | 52,434,000 | ||||||||||||||||||||||||||||||||||||
| deferred revenue, net of current portion | 54,204,000 | 54,204,000 | 54,204,000 | 54,204,000 | 54,204,000 | 54,204,000 | 60,667,000 | 60,667,000 | 60,667,000 | 60,667,000 | 60,667,000 | 64,667,000 | 68,888,000 | 60,888,000 | 60,888,000 | 60,888,000 | 55,221,000 | 56,667,000 | 73,984,000 | 80,821,000 | 138,406,000 | 141,770,000 | 163,207,000 | 82,379,000 | 75,911,000 | 105,865,000 | 115,614,000 | 104,100,000 | 104,929,000 | 91,972,000 | 94,725,000 | 97,851,000 | 100,953,000 | 104,033,000 | 26,000,000 | ||||
| other non-current liabilities | 4,592,000 | 6,363,000 | 3,072,000 | 3,281,000 | 3,768,000 | 3,473,000 | 1,800,000 | 27,500,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 293,000 | 301,000 | 305,000 | 311,000 | 317,000 | 325,000 | 328,000 | 331,000 | 16,000 | 19,000 | 21,000 | 24,000 | 27,000 | |||||||||||||
| total liabilities | 191,392,000 | 201,232,000 | 207,315,000 | 151,933,000 | 152,792,000 | 145,947,000 | 150,056,000 | 144,188,000 | 142,036,000 | 146,632,000 | 153,641,000 | 116,284,000 | 115,419,000 | 110,348,000 | 123,841,000 | 130,225,000 | 142,519,000 | 142,298,000 | 179,016,000 | 156,005,000 | 228,709,000 | 232,170,000 | 246,448,000 | 162,369,000 | 162,563,000 | 161,754,000 | 184,224,000 | 163,181,000 | 162,198,000 | 156,467,000 | 165,180,000 | 161,339,000 | 183,845,000 | 188,580,000 | 94,575,000 | 71,977,000 | 62,272,000 | 47,445,000 | 32,562,000 |
| stockholders’ equity | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding | |||||||||||||||||||||||||||||||||||||||
| common stock | 9,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 8,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | |
| additional paid-in capital | 1,616,931,000 | 1,606,855,000 | 1,602,441,000 | 1,598,152,000 | 1,593,350,000 | 1,588,018,000 | 1,580,241,000 | 1,574,382,000 | 1,569,651,000 | 1,446,912,000 | 1,442,405,000 | 1,436,422,000 | 1,430,461,000 | 1,423,476,000 | 1,411,827,000 | 1,403,114,000 | 1,390,606,000 | 1,359,987,000 | 1,058,823,000 | 1,043,892,000 | 1,037,100,000 | 820,813,000 | 811,546,000 | 721,397,000 | 671,522,000 | 661,852,000 | 652,464,000 | 615,749,000 | 607,311,000 | 584,825,000 | 514,002,000 | 447,468,000 | 428,129,000 | 423,080,000 | 320,129,000 | 316,322,000 | 312,456,000 | 307,448,000 | 5,234,000 |
| accumulated other comprehensive income | 15,000 | 88,000 | 268,000 | 522,000 | -442,000 | -326,000 | 198,000 | -46,000 | -48,000 | 183,000 | 694,000 | 107,000 | 39,000 | 45,000 | 29,000 | ||||||||||||||||||||||||
| accumulated deficit | -1,597,766,000 | -1,544,531,000 | -1,468,443,000 | -1,423,048,000 | -1,360,907,000 | -1,293,300,000 | -1,231,350,000 | -1,212,476,000 | -1,167,457,000 | -1,127,167,000 | -1,078,131,000 | -1,017,393,000 | -961,667,000 | -908,214,000 | -857,699,000 | -816,263,000 | -777,181,000 | -721,925,000 | -665,197,000 | -602,698,000 | -610,517,000 | -586,945,000 | -549,221,000 | -511,451,000 | -478,510,000 | -444,724,000 | -416,278,000 | -391,223,000 | -375,985,000 | -337,262,000 | -305,850,000 | -269,661,000 | -243,062,000 | -216,623,000 | -185,526,000 | -146,150,000 | -125,130,000 | -106,089,000 | -88,348,000 |
| total stockholders’ equity | 19,189,000 | 62,420,000 | 134,274,000 | 175,634,000 | 232,009,000 | 294,400,000 | 349,097,000 | 360,462,000 | 399,917,000 | 317,473,000 | 360,680,000 | 414,745,000 | 465,414,000 | 512,760,000 | 553,642,000 | 586,794,000 | 613,361,000 | 637,996,000 | 393,586,000 | 441,152,000 | 426,772,000 | 234,567,000 | 262,437,000 | 209,990,000 | 193,062,000 | 217,162,000 | 236,162,000 | 224,449,000 | 231,332,000 | 247,515,000 | 208,080,000 | 177,788,000 | 185,004,000 | 206,461,000 | 134,607,000 | 170,176,000 | 187,330,000 | 201,363,000 | |
| total liabilities and stockholders’ equity | 210,581,000 | 263,652,000 | 341,589,000 | 327,567,000 | 384,801,000 | 440,347,000 | 499,153,000 | 504,650,000 | 541,953,000 | 464,105,000 | 514,321,000 | 531,029,000 | 580,833,000 | 623,108,000 | 677,483,000 | 717,019,000 | 755,880,000 | 780,294,000 | 572,602,000 | 597,157,000 | 655,481,000 | 466,737,000 | 508,885,000 | 372,359,000 | 355,625,000 | 378,916,000 | 420,386,000 | 387,630,000 | 393,530,000 | 403,982,000 | 373,260,000 | 339,127,000 | 368,849,000 | 395,041,000 | |||||
| accumulated other comprehensive loss | -1,452,000 | -2,285,000 | -2,279,000 | -3,601,000 | -4,291,000 | -3,387,000 | -2,509,000 | -493,000 | -64,000 | -71,000 | -73,000 | -29,000 | -82,000 | -52,000 | -76,000 | -23,000 | -67,000 | ||||||||||||||||||||||
| other current liabilities | 3,135,000 | 4,027,000 | 3,515,000 | 2,682,000 | 1,558,000 | 1,033,000 | 1,911,000 | 2,048,000 | 980,000 | 944,000 | 908,000 | 900,000 | 831,000 | 1,131,000 | 13,285,000 | 986,000 | 547,000 | ||||||||||||||||||||||
| construction financing lease obligation, net of current portion | 32,417,000 | 32,694,000 | 32,944,000 | 33,190,000 | 33,431,000 | 33,667,000 | 33,878,000 | 33,929,000 | 35,096,000 | 32,048,000 | |||||||||||||||||||||||||||||
| commitments and contingencies | |||||||||||||||||||||||||||||||||||||||
| right-of-use asset | 17,681,000 | 17,477,000 | 18,480,000 | ||||||||||||||||||||||||||||||||||||
| operating lease liability | 4,448,000 | 3,648,000 | 3,519,000 | ||||||||||||||||||||||||||||||||||||
| operating lease liability, net of current portion | 13,202,000 | 13,784,000 | 14,859,000 | ||||||||||||||||||||||||||||||||||||
| notes payable | 7,500,000 | 15,000,000 | 15,000,000 | 10,000,000 | |||||||||||||||||||||||||||||||||||
| accumulated other comprehensive gain | 1,000 | ||||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ equity | |||||||||||||||||||||||||||||||||||||||
| deferred rent, current portion | 18,000 | 31,000 | 62,000 | 88,000 | |||||||||||||||||||||||||||||||||||
| deferred rent, net of current portion | 380,000 | 353,000 | 212,000 | 71,000 | |||||||||||||||||||||||||||||||||||
| warrant to purchase redeemable securities | 289,000 | ||||||||||||||||||||||||||||||||||||||
| series a-1 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 21,320,000 shares authorized at december 31, 2016 and december 31, 2015, respectively; no shares and 21,260,000 shares issued and outstanding at december 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series a-2 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 16,890,699 shares authorized, issued and outstanding at december 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value per share: no shares and 26,666,660 shares authorized, issued and outstanding at december 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value per share: 5,000,000 shares and no shares authorized, at december 31, 2016 and december 31, 2015, respectively; no shares issued or outstanding at december 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 229,182,000 | 242,153,000 | 249,602,000 | 248,808,000 | |||||||||||||||||||||||||||||||||||
| deferred revenue | 25,800,000 | 25,642,000 | 25,479,000 | 25,321,000 | |||||||||||||||||||||||||||||||||||
| series a-1 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 21,320,000 shares authorized at september 30, 2016 and december 31, 2015, respectively; no shares and 21,260,000 shares issued and outstanding at september 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series a-2 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 16,890,699 shares authorized, issued and outstanding at september 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value per share: no shares and 26,666,660 shares authorized, issued and outstanding at september 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,000,000 shares and no shares authorized, at september 30, 2016 and december 31, 2015, respectively; no shares issued or outstanding at september 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| construction financing lease obligation | 22,676,000 | 11,649,000 | |||||||||||||||||||||||||||||||||||||
| series a-1 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 21,320,000 shares authorized at june 30, 2016 and december 31, 2015, respectively; no shares and 21,260,000 shares issued and outstanding at june 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series a-2 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 16,890,699 shares authorized, issued and outstanding at june 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value per share: no shares and 26,666,660 shares authorized, issued and outstanding at june 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,000,000 shares and no shares authorized at june 30, 2016 and december 31, 2015, respectively; no shares issued or outstanding at june 30, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series a-1 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 21,320,000 shares authorized at march 31, 2016 and december 31, 2015, respectively; no shares and 21,260,000 shares issued and outstanding at march 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series a-2 redeemable convertible preferred stock, 0.0001 par value per share: no shares and 16,890,699 shares authorized, issued and outstanding at march 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value per share: no shares and 26,666,660 shares authorized, issued and outstanding at march 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,000,000 shares and no shares authorized at march 31, 2016 and december 31, 2015, respectively; no shares issued or outstanding at march 31, 2016 and december 31, 2015, respectively | |||||||||||||||||||||||||||||||||||||||
| other non-current assets | 2,248,000 | ||||||||||||||||||||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ deficit | |||||||||||||||||||||||||||||||||||||||
| anti-dilution protection liability | |||||||||||||||||||||||||||||||||||||||
| preferred stock tranche liability | |||||||||||||||||||||||||||||||||||||||
| equipment loan, current portion, net of discount | |||||||||||||||||||||||||||||||||||||||
| equipment loan, net of current portion and discount | |||||||||||||||||||||||||||||||||||||||
| series a-1 redeemable convertible preferred stock, 0.0001 par value per share: 21,320,000 shares authorized at december 31, 2015 and 2014, respectively; 21,260,000 shares issued and outstanding at december 31, 2015 and 2014, respectively; aggregate liquidation preference of 21,260,000 at december 31, 2015 | 21,137,000 | ||||||||||||||||||||||||||||||||||||||
| series a-2 redeemable convertible preferred stock, 0.0001 par value per share: 16,890,699 and 16,698,672 shares authorized at december 31, 2015 and 2014, respectively; 16,890,699, and 0 shares issued and outstanding at december 31, 2015 and 2014, respectively; aggregate liquidation preference of 21,990,000 at december 31, 2015 | 59,027,000 | ||||||||||||||||||||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value per share: 26,666,660 and no shares authorized at december 31, 2015, and 2014, respectively; 26,666,660, and 0 shares issued and outstanding at december 31, 2015 and 2014, respectively; aggregate liquidation preference of 119,999,970 at december 31, 2015 | 119,751,000 | ||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit | |||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -83,114,000 | ||||||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 149,363,000 | ||||||||||||||||||||||||||||||||||||||
| collaboration revenue | 1,629,000 | ||||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||
| research and development | 18,846,000 | ||||||||||||||||||||||||||||||||||||||
| general and administrative | 18,095,000 | ||||||||||||||||||||||||||||||||||||||
| total operating expenses | 36,941,000 | ||||||||||||||||||||||||||||||||||||||
| operating income | -35,312,000 | ||||||||||||||||||||||||||||||||||||||
| other income | -37,445,000 | ||||||||||||||||||||||||||||||||||||||
| interest expense | -143,000 | ||||||||||||||||||||||||||||||||||||||
| total other income | -37,588,000 | ||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -72,900,000 | ||||||||||||||||||||||||||||||||||||||
| reconciliation of net income to net income attributable to common stockholders: | |||||||||||||||||||||||||||||||||||||||
| net income | -72,900,000 | ||||||||||||||||||||||||||||||||||||||
| accretion of redeemable convertible preferred stock to redemption value | -394,000 | ||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -73,294,000 | ||||||||||||||||||||||||||||||||||||||
| net income per share | -28,550 | ||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 2,566,916,000 |
We provide you with 20 years of balance sheets for Editas Medicine stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Editas Medicine. Explore the full financial landscape of Editas Medicine stock with our expertly curated balance sheets.
The information provided in this report about Editas Medicine stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.